SUROTOMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C77H101N17O26
Molecular Weight	1680.7241
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCC1=CC=C(C=C1)C(\C)=C\C(=O)N[C@@H](CC2=CNC3=CC=CC=C23)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4[C@@H](C)OC(=O)[C@H](CC(=O)C5=C(N)C=CC=C5)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC4=O)[C@H](C)CC(O)=O

InChI

InChIKey=DYNMYYRPPFVAKR-CWXHRMTKSA-N

InChI=1S/C77H101N17O26/c1-6-7-8-14-41-20-22-42(23-21-41)37(2)25-58(98)86-49(27-43-33-81-47-18-12-10-15-44(43)47)71(113)89-50(29-57(80)97)72(114)91-53(32-64(107)108)73(115)94-66-40(5)120-77(119)54(28-56(96)45-16-9-11-17-46(45)79)92-76(118)65(38(3)26-61(101)102)93-74(116)55(36-95)87-60(100)34-82-68(110)51(30-62(103)104)88-67(109)39(4)84-70(112)52(31-63(105)106)90-69(111)48(19-13-24-78)85-59(99)35-83-75(66)117/h9-12,15-18,20-23,25,33,38-40,48-55,65-66,81,95H,6-8,13-14,19,24,26-32,34-36,78-79H2,1-5H3,(H2,80,97)(H,82,110)(H,83,117)(H,84,112)(H,85,99)(H,86,98)(H,87,100)(H,88,109)(H,89,113)(H,90,111)(H,91,114)(H,92,118)(H,93,116)(H,94,115)(H,101,102)(H,103,104)(H,105,106)(H,107,108)/b37-25+/t38-,39-,40-,48+,49+,50-,51+,52+,53+,54+,55-,65+,66+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C77H101N17O26
Molecular Weight	1680.7241
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	13 / 13
E/Z Centers	5
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28347318 | https://www.ncbi.nlm.nih.gov/pubmed/28961905 | https://www.ncbi.nlm.nih.gov/pubmed/30307842

Surotomycin is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. Surotomycin has a fourfold greater in vitro potency than vancomycin against C. Difficile and other Gram-positive bacteria with minimal impact on the Gram-negative organisms of the intestinal microbiota. Surotomycin, given orally, has been shown to be highly effective against both initial and relapsing hamster Clostridium difficile-associated diarrhea, with a potency similar to vancomycin. Surotomycin is non-inferior to vancomycin and offers a promising alternative for the treatment and prevention of C. diff infection.

Originator

Approval Year

PubMed

Title	Date	PubMed
Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.	2017 Mar 28	28347318

Patents

Sample Use Guides

In Vivo Use Guide

500, 1000, 2000, 4000 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:14:11 UTC 2023` Edited by `admin` on `Fri Dec 15 16:14:11 UTC 2023`
Record UNII	ON0N776N05
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SUROTOMYCIN

Official Name

English

surotomycin [INN]

Common Name

English

SUROTOMYCIN [USAN]

Common Name

English

CB-183,315

Code

English

CB-183315

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C258